Eli Lilly Trial Wins And Gene Editing Progress Versus Current Valuation

Simply Wall St

Thu, February 19, 2026 at 10:15 AM GMT+9 3 min read

In this article:

•                                       StockStory Top Pick 
  

  LLY

  -1.50%

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.

Eli Lilly (NYSE:LLY) reported successful results from the TOGETHER-PsO Phase 3b trial combining Taltz and Zepbound for patients with psoriasis and obesity.

The company reached a second key milestone in its CRISPR-based gene editing collaboration with Scribe Therapeutics.

The LIBRETTO-432 Phase 3 trial of Retevmo in early-stage RET fusion positive lung cancer met its primary goal in the adjuvant setting.

Eli Lilly, trading at $1,020.56, has seen a very large 3-year return and a 424.5% 5-year return, with shares up 18.6% over the past year. Recent short-term moves have been mixed, with a 0.5% gain over 7 days, a 1.7% decline over 30 days, and a 5.5% decline year to date. In that context, these new clinical results add fresh information on how the pipeline is evolving across immunology, obesity, oncology, and genetic medicine.

For investors following NYSE:LLY, the combination psoriasis and obesity data, progress in CRISPR based therapies, and early-stage lung cancer results widen the set of potential future revenue streams tied to late-stage and partnered programs. Key points from here include how regulators respond, how quickly these therapies move through approval and commercialization paths, and how Lilly balances investment across traditional drugs and genetic medicine as the story develops.

Stay updated on the most important news stories for Eli Lilly by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Eli Lilly.

NYSE:LLY Earnings & Revenue Growth as at Feb 2026

3 things going right for Eli Lilly that this headline doesn’t cover.

Quick Assessment

**✅ Price vs Analyst Target**: At US$1,020.56, Eli Lilly trades about 15% below the US$1,202 consensus price target.

**✅ Simply Wall St Valuation**: Shares are described as trading 29.2% below estimated fair value, suggesting upside relative to that model.

**❌ Recent Momentum**: The stock has a 30 day return of about 1.7% decline, so recent sentiment has been soft despite the pipeline news.

There is only one way to know the right time to buy, sell or hold Eli Lilly. Head to Simply Wall St’s company report for the latest analysis of Eli Lilly’s Fair Value.

Key Considerations

📊 The positive results for Taltz plus Zepbound, Scribe gene editing progress, and Retevmo in early lung cancer expand the set of late stage and partnered assets that could support future earnings.

📊 Watch how regulators respond to these trials, any updates to revenue and earnings forecasts, and whether the current P/E of 44.2 stays aligned with Lilly's growth profile.

⚠️ With 2 identified risks including debt concerns and a high level of non cash earnings, investors may want to monitor balance sheet trends and earnings quality as pipeline spending continues.

 






Story Continues  

Dig Deeper

For the full picture including more risks and rewards, check out the complete Eli Lilly analysis. Alternatively, you can visit the community page for Eli Lilly to see how other investors believe this latest news will impact the company’s narrative.

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include LLY.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info